DK2907522T1 - Fremgangsmåde til øgning af knoglesejhed og -stivhed og nedsættelse af frakturer - Google Patents
Fremgangsmåde til øgning af knoglesejhed og -stivhed og nedsættelse af frakturer Download PDFInfo
- Publication number
- DK2907522T1 DK2907522T1 DK15152726.4T DK15152726T DK2907522T1 DK 2907522 T1 DK2907522 T1 DK 2907522T1 DK 15152726 T DK15152726 T DK 15152726T DK 2907522 T1 DK2907522 T1 DK 2907522T1
- Authority
- DK
- Denmark
- Prior art keywords
- pth
- human
- fractures
- stiffness
- procedure
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 2
- 210000000988 bone and bone Anatomy 0.000 title 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims 7
- 108090000445 Parathyroid hormone Proteins 0.000 claims 3
- 102000003982 Parathyroid hormone Human genes 0.000 claims 3
- 239000000199 parathyroid hormone Substances 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Steroid Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Claims (4)
1. Human PTH(l-34) til anvendelse i en fremgangsmåde til nedsættelse af hyppigheden og/eller alvorligheden af fraktur, hos et menneske med risiko for eller som har osteoporose, ved administration af PTH(l-34) ved subkutan injektion ved en dosis på mindre end 1 pg/kg/dag.
2. Human PTH(l-34) til anvendelse ifølge krav 1, hvor mennesket også modtager effektive doser calcium og vitamin D.
3. Human PTH(l-34) til anvendelse ifølge et hvilket som helst af de foregående krav, hvor PTH(l-34) administreres i 12-24 måneder og derefter afvænning i mindst 6 måneder.
4. Human PTH(l-34) til anvendelse ifølge et hvilket som helst af de foregående krav, hvor PTH(l-34) administreres som en stabiliseret opløsning omfattende et stabiliseringsmiddel, et buffermiddel og et konserveringsmiddel.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9715198P | 1998-08-19 | 1998-08-19 | |
| US9974698P | 1998-09-10 | 1998-09-10 | |
| EP10180447.4A EP2266598B1 (en) | 1998-08-19 | 1999-08-19 | Method of increasing bone toughness and stiffness and reducing fractures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2907522T1 true DK2907522T1 (da) | 2015-10-19 |
| DK2907522T3 DK2907522T3 (da) | 2017-10-23 |
Family
ID=26792729
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99942350T DK1059933T3 (da) | 1998-08-19 | 1999-08-19 | Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur |
| DK10180447.4T DK2266598T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud |
| DK15152726.4T DK2907522T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til øgning af knoglehårdhed og stivhed og reduktion af frakturer |
| DK06027055.0T DK1769804T3 (da) | 1998-08-19 | 1999-08-19 | hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK99942350T DK1059933T3 (da) | 1998-08-19 | 1999-08-19 | Anvendelse af parathyroideahormon bestående af aminosyresekvens 1-34 af humant parathyroideahormon til reduktion af risikoen for både hvirvel- og ikke-hvirvel knoglefraktur |
| DK10180447.4T DK2266598T3 (da) | 1998-08-19 | 1999-08-19 | Fremgangsmåde til at øge knoglehårdhed og -stivhed og at reducere brud |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06027055.0T DK1769804T3 (da) | 1998-08-19 | 1999-08-19 | hPTH(1-34) til anvendelse ved forebyggelse eller reduktion af forekomsten eller voldsomheden af vertebral og/eller ikke-vertebral fraktur hos en mand |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US6977077B1 (da) |
| EP (3) | EP2907522B1 (da) |
| JP (5) | JP2002523375A (da) |
| KR (1) | KR100454207B1 (da) |
| CN (1) | CN1205997C (da) |
| AR (1) | AR033639A1 (da) |
| AT (1) | ATE231000T1 (da) |
| AU (1) | AU746277B2 (da) |
| BR (1) | BR9909445A (da) |
| CA (1) | CA2325371C (da) |
| CO (1) | CO5130020A1 (da) |
| CY (2) | CY1113343T1 (da) |
| CZ (1) | CZ301017B6 (da) |
| DE (2) | DE69904918T2 (da) |
| DK (4) | DK1059933T3 (da) |
| DZ (1) | DZ2873A1 (da) |
| EA (1) | EA003362B1 (da) |
| ES (4) | ES2621653T3 (da) |
| HK (3) | HK1030545A1 (da) |
| HR (1) | HRP20000755A2 (da) |
| HU (2) | HU1200430D0 (da) |
| ID (1) | ID29039A (da) |
| IL (2) | IL138829A0 (da) |
| MY (1) | MY129227A (da) |
| NO (2) | NO323984B1 (da) |
| NZ (1) | NZ507056A (da) |
| PE (1) | PE20001089A1 (da) |
| PL (1) | PL201688B1 (da) |
| PT (4) | PT2266598T (da) |
| TR (1) | TR200003455T2 (da) |
| TW (1) | TW576747B (da) |
| UA (1) | UA72205C2 (da) |
| WO (1) | WO2000010596A1 (da) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770623B1 (en) * | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| AR033639A1 (es) * | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| WO2001022093A1 (en) * | 1999-09-20 | 2001-03-29 | Eli Lilly And Company | Method for monitoring treatment with a parathyroid hormone |
| US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
| CA2472472A1 (en) * | 2002-01-10 | 2003-07-24 | Osteotrophin Llc | Treatment of bone disorders with skeletal anabolic drugs |
| US8088734B2 (en) | 2003-01-21 | 2012-01-03 | Unigene Laboratories Inc. | Oral delivery of peptides |
| EP1667689A1 (en) * | 2003-09-19 | 2006-06-14 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone |
| US20060052305A1 (en) * | 2004-05-10 | 2006-03-09 | Nastech Pharmaceutical Company Inc. | Method of treating osteoporosis using intranasal parathyroid hormone |
| US20060127320A1 (en) * | 2004-05-10 | 2006-06-15 | Nastech Pharmaceutical Company Inc. | Method of delivering parathyroid hormone to a human |
| RU2006143544A (ru) * | 2004-05-10 | 2008-06-20 | Нэстек Фармасьютикал Кампани Инк. (Us) | Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона |
| US20060189533A1 (en) * | 2004-05-10 | 2006-08-24 | Nastech Pharmaceutical Company Inc. | Stable pharmaceutical dosage forms of teriparatide |
| CA2566032A1 (en) | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
| US7648965B2 (en) | 2004-05-14 | 2010-01-19 | Unigene Laboratories Inc. | Method for fostering bone formation and preservation |
| US20060069021A1 (en) * | 2004-08-13 | 2006-03-30 | Nastech Pharmaceutical Company Inc. | Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs |
| WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
| US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
| EP1879608A4 (en) * | 2005-05-11 | 2009-11-11 | Unigene Lab Inc | METHOD FOR STIMULATING BONE FORMATION AND PRESERVATION |
| US20070173447A1 (en) * | 2005-10-25 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent |
| WO2007059470A2 (en) * | 2005-11-10 | 2007-05-24 | Board Of Control Of Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US20080051332A1 (en) * | 2005-11-18 | 2008-02-28 | Nastech Pharmaceutical Company Inc. | Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone |
| US20080119408A1 (en) * | 2006-07-07 | 2008-05-22 | Nastech Pharmaceutical Company Inc. | Pth formulations for intranasal delivery |
| EP1961765A1 (en) * | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| ATE543520T1 (de) | 2007-04-13 | 2012-02-15 | Kuros Biosurgery Ag | Polymergewebeversiegelung |
| US20110137243A1 (en) * | 2007-09-06 | 2011-06-09 | Abbott Cardiovascular Systems Inc. | Coating On A Balloon Device |
| US9457056B2 (en) * | 2007-12-04 | 2016-10-04 | Ben-Gurion University Of The Negev Research And Development Authority | Peptides comprising alternating hydrophobic and anionic amino acids for treatment of osteoporosis |
| CA2710798A1 (en) | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
| KR20190095552A (ko) * | 2009-09-09 | 2019-08-14 | 아사히 가세이 파마 가부시키가이샤 | 1회당 100∼200 단위의 ｐｔｈ가 주 1회 투여되는 것을 특징으로 하는, ｐｔｈ 함유 골다공증 치료/예방제 |
| AU2009356227A1 (en) | 2009-12-07 | 2012-06-21 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US9295663B2 (en) | 2010-07-14 | 2016-03-29 | Abbott Cardiovascular Systems Inc. | Drug coated balloon with in-situ formed drug containing microspheres |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| EP2686027B1 (en) | 2011-03-16 | 2021-05-05 | Kuros Biosurgery AG | Pharmaceutical formulation for use in spinal fusion |
| US20140088014A1 (en) | 2011-06-07 | 2014-03-27 | Asahi Kasei Pharma Corporation | Freeze-dried preparation containing high-purity pth and method for producing same |
| US9700485B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| AU2017214277B2 (en) * | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
| EP3576774A4 (en) * | 2017-02-01 | 2020-10-07 | The Johns Hopkins University | PARATHYROID HORMONE AND REGENERATION OF DEGENERATIVE DISCS |
| JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
| CN111447943A (zh) | 2018-10-29 | 2020-07-24 | 旭化成制药株式会社 | 以按每周2次的频率给予特立帕肽或其盐为特征的骨质疏松症的预防或治疗方法 |
| EP4010360A1 (en) | 2019-08-09 | 2022-06-15 | Flagship Pioneering Innovations VI, LLC | Modulators of parathyroid hormone receptor (pthr1) |
| GB2590692A (en) * | 2019-12-24 | 2021-07-07 | Corthotec Ltd | Composition for improved bone fracture healing |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4086196A (en) | 1975-03-28 | 1978-04-25 | Armour Pharmaceutical Company | Parathyroid hormone |
| IL78342A (en) * | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5208041A (en) | 1991-05-23 | 1993-05-04 | Allelix Biopharmaceuticals Inc. | Essentially pure human parathyroid hormone |
| CA2126299C (en) | 1994-06-20 | 2000-12-12 | Gordon E. Willick | Parathyroid hormone analogues for the treatment of osteoporosis |
| JPH0873376A (ja) * | 1994-09-07 | 1996-03-19 | Asahi Chem Ind Co Ltd | 骨粗鬆症治療薬 |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| EP0800405A4 (en) * | 1994-12-19 | 1998-11-11 | Beth Israel Hospital | CONTINUOUS ADMINISTRATION OF LOW DOSES OF HORMONE PARATHYRO DIENNE OR ITS AGONIST |
| HU218940B (hu) * | 1994-12-22 | 2001-01-29 | Astra Aktiebolag | Paratiroid hormont (PHT) tartalmazó, inhalációs célra szolgáló gyógyszerkészítmény, eljárás előállítására, alkalmazása inhalációs készülék töltésére és ezt tartalmazó inhalációs készülék |
| JPH08310965A (ja) * | 1995-05-16 | 1996-11-26 | Chugai Pharmaceut Co Ltd | 骨癒合促進剤 |
| EP1005359B1 (en) * | 1997-09-09 | 2005-06-15 | F. Hoffmann-La Roche Ag | FRACTURE HEALING USING PTHrP ANALOGS |
| ZA9811127B (en) | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| AR033639A1 (es) | 1998-08-19 | 2004-01-07 | Lilly Co Eli | Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis |
| US20040033950A1 (en) * | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| US6907597B1 (en) | 2000-10-13 | 2005-06-14 | Ati International Srl | Method and apparatus for constructing an executable program in memory |
| US6967759B2 (en) | 2001-12-31 | 2005-11-22 | Texas Instruments Incorporated | Pulse width modulation sequence generation |
| JP5796714B2 (ja) | 2012-01-13 | 2015-10-21 | 株式会社リコー | 定着装置及び画像形成装置 |
| EP2949301B1 (en) | 2014-05-27 | 2018-04-18 | The Procter and Gamble Company | Absorbent core with curved and straight absorbent material areas |
-
1999
- 1999-08-18 AR ARP990104133A patent/AR033639A1/es unknown
- 1999-08-18 DZ DZ990173A patent/DZ2873A1/xx active
- 1999-08-19 HU HUP1200430 patent/HU1200430D0/hu not_active Application Discontinuation
- 1999-08-19 ES ES10180447.4T patent/ES2621653T3/es not_active Expired - Lifetime
- 1999-08-19 HU HU0101594A patent/HU230697B1/hu unknown
- 1999-08-19 KR KR10-2001-7002092A patent/KR100454207B1/ko not_active IP Right Cessation
- 1999-08-19 CN CNB998083534A patent/CN1205997C/zh not_active Expired - Lifetime
- 1999-08-19 US US09/647,278 patent/US6977077B1/en not_active Expired - Lifetime
- 1999-08-19 DE DE69904918T patent/DE69904918T2/de not_active Expired - Lifetime
- 1999-08-19 PE PE1999000839A patent/PE20001089A1/es not_active Application Discontinuation
- 1999-08-19 IL IL13882999A patent/IL138829A0/xx unknown
- 1999-08-19 PT PT101804474T patent/PT2266598T/pt unknown
- 1999-08-19 WO PCT/US1999/018961 patent/WO2000010596A1/en active IP Right Grant
- 1999-08-19 CO CO99052525A patent/CO5130020A1/es unknown
- 1999-08-19 DK DK99942350T patent/DK1059933T3/da active
- 1999-08-19 EA EA200001015A patent/EA003362B1/ru not_active IP Right Cessation
- 1999-08-19 NZ NZ507056A patent/NZ507056A/en not_active IP Right Cessation
- 1999-08-19 EP EP15152726.4A patent/EP2907522B1/en not_active Revoked
- 1999-08-19 CZ CZ20004134A patent/CZ301017B6/cs not_active IP Right Cessation
- 1999-08-19 PT PT06027055T patent/PT1769804E/pt unknown
- 1999-08-19 PL PL343595A patent/PL201688B1/pl not_active IP Right Cessation
- 1999-08-19 DE DE15152726.4T patent/DE15152726T1/de active Pending
- 1999-08-19 DK DK10180447.4T patent/DK2266598T3/da active
- 1999-08-19 UA UA2000095457A patent/UA72205C2/uk unknown
- 1999-08-19 PT PT15152726T patent/PT2907522T/pt unknown
- 1999-08-19 BR BR9909445-2A patent/BR9909445A/pt not_active Application Discontinuation
- 1999-08-19 PT PT99942350T patent/PT1059933E/pt unknown
- 1999-08-19 AT AT99942350T patent/ATE231000T1/de not_active IP Right Cessation
- 1999-08-19 CA CA002325371A patent/CA2325371C/en not_active Expired - Lifetime
- 1999-08-19 ES ES06027055T patent/ES2393200T3/es not_active Expired - Lifetime
- 1999-08-19 ES ES99942350T patent/ES2190244T3/es not_active Expired - Lifetime
- 1999-08-19 JP JP2000565916A patent/JP2002523375A/ja active Pending
- 1999-08-19 EP EP10180447.4A patent/EP2266598B1/en not_active Expired - Lifetime
- 1999-08-19 ID IDW20010612A patent/ID29039A/id unknown
- 1999-08-19 EP EP99942350A patent/EP1059933B1/en not_active Revoked
- 1999-08-19 TR TR2000/03455T patent/TR200003455T2/xx unknown
- 1999-08-19 ES ES15152726.4T patent/ES2549551T3/es not_active Expired - Lifetime
- 1999-08-19 DK DK15152726.4T patent/DK2907522T3/da active
- 1999-08-19 AU AU55750/99A patent/AU746277B2/en not_active Expired
- 1999-08-19 MY MYPI99003553A patent/MY129227A/en unknown
- 1999-08-19 DK DK06027055.0T patent/DK1769804T3/da active
- 1999-10-26 TW TW088114185A patent/TW576747B/zh not_active IP Right Cessation
-
2000
- 2000-10-03 IL IL138829A patent/IL138829A/en unknown
- 2000-11-06 HR HR20000755A patent/HRP20000755A2/hr not_active Application Discontinuation
- 2000-11-24 NO NO20005947A patent/NO323984B1/no not_active IP Right Cessation
-
2001
- 2001-02-14 HK HK01101056A patent/HK1030545A1/xx unknown
-
2005
- 2005-04-05 US US11/098,894 patent/US7163684B2/en not_active Expired - Lifetime
-
2007
- 2007-06-11 NO NO20072983A patent/NO20072983L/no not_active Application Discontinuation
- 2007-10-04 HK HK07110798.6A patent/HK1102496A1/xx unknown
-
2010
- 2010-10-29 JP JP2010244314A patent/JP2011021035A/ja not_active Withdrawn
-
2012
- 2012-11-14 CY CY20121101096T patent/CY1113343T1/el unknown
-
2014
- 2014-03-25 JP JP2014061763A patent/JP6177718B2/ja not_active Expired - Lifetime
- 2014-10-03 JP JP2014204577A patent/JP2015028065A/ja not_active Withdrawn
-
2016
- 2016-01-18 HK HK16100519.4A patent/HK1212602A1/zh not_active IP Right Cessation
-
2017
- 2017-06-26 JP JP2017124301A patent/JP2017190332A/ja not_active Withdrawn
- 2017-10-13 CY CY20171101077T patent/CY1119552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2907522T1 (da) | Fremgangsmåde til øgning af knoglesejhed og -stivhed og nedsættelse af frakturer | |
| Rodriguez-Merchan et al. | Nonunion: general principles and experimental data | |
| DE3851776D1 (de) | Verwendung von IGF-II zur Behandlung von Knochenkrankheiten. | |
| IL78342A (en) | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof | |
| BR9402902A (pt) | Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica. | |
| WO2002076472A3 (en) | Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs | |
| ATE204178T1 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
| EA200000748A1 (ru) | Способ введения мономерных аналогов инсулина | |
| AR032567A1 (es) | Propeptidos gdf modificados y estabilizados y usos de los mismos | |
| NO20045507L (no) | Injiserbare faste hyaluronsyrebaerere for levering av osteogene proteiner | |
| WO2003079993A3 (en) | hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION | |
| NO20040598L (no) | 5-CNAC som oralt avleveringsmiddel for paratyreoidhormonfragmenter. | |
| Cummings | How drugs decrease fracture risk: lessons from trials | |
| Kesemenli et al. | Treatment of traumatic bone defects by bone transport | |
| WO2000012047A3 (en) | Enhancement of return to independent living status with a growth hormone secretagogue | |
| AR036591A1 (es) | Uso de la hl en hiperestimulacion ovarica controlada | |
| Saraph et al. | Tibial lengthening over nails in children using modified Ender nails: preliminary results of a new treatment | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
| WO2003032961A3 (en) | Methods for preventing and treating bone loss with steroid compounds | |
| BR0316123A (pt) | Formulação farmacêutica aquosa, uso de uma formulação farmacêutica aquosa, e, método de tratamento de um paciente com necessidade de tratamento antitrombótico | |
| WO2003097690A3 (en) | Pth derivatives resistant to skin proteases | |
| BR0113115A (pt) | Tratamento de hepatite c com timosina, interferon e ribavirina | |
| Yamagata et al. | Clinical Experiences of Compression Hip Screw System for Femoral Neck Fractures in the Aged | |
| SU820814A1 (ru) | Фиксатор дл компрессионного остео-СиНТЕзА пРи КОРРТигиРующиХ ОСТЕОТОМи Х | |
| JPS56103114A (en) | Drug for osteoporosis comprising 24r- hydroxycholecalciferol |